Farmanews.com

Notas de Prensa  

06 de febrero de 2007

Amgen CEO Kevin Sharer to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 6, 2007--Amgen (NASDAQ:AMGN) Chairman and CEO Kevin Sharer will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Thursday, Feb. 8, 2007 beginning at 9:20 a.m. Eastern Time. Live audio of the presentation will be available over the Internet and can be accessed from Amgen´s Web site, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are noted on Amgen´s Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science´s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people´s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks David Polk, 805-447-4613 or 805-490-0661 (media) Arvind Sood, 805-447-1060 (investors) SOURCE: Amgen

Subir  

Subir notas de prensa y convocatorias

Próximas convocatorias   


  • Día Mundial del Ictus
  • Fecha: 27 de noviembre de 2017
  • Lugar: Instituto de la Mujer y para la Igualdad de Oportunidades C/ Condesa de Venadito, 34. Madrid

Ver todas

Especialidades  

Busca notas de prensa por especialidad médica o enfermedad.



Ver todas

Archivo  

Busca notas de prensa por su fecha de edición.

  Selecciona el año


Copyright © 2017, Farmavet, S.L. Todos los derechos reservados.